Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is a 2-arm, double-blind, parallel, randomized, placebo-controlled clinical study, with
12 weeks of therapy to evaluate the efficacy and safety of DLBS3233 in improving metabolic
control in newly diagnosed type-2-diabetic patients, as measured by A1c level, fasting and
2-hours post-prandial plasma glucose, fasting insulin level, HOMA-IR, HOMA-B, adiponectin
level, lipid profile, and body weight.